US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Articles published by Kyowa Kirin

News headline image
New Analyses Advance Understanding of Long-Term Survival Outcomes with Mogamulizumab in Mycosis Fungoides and Sézary Syndrome
From Kyowa Kirin
Via GlobeNewswire
News headline image
New PROSPER Data Demonstrate Real-World Impact of Mogamulizumab on Symptoms and Health-Related Quality of Life in Mycosis Fungoides and Sézary Syndrome
From Kyowa Kirin
Via GlobeNewswire
News headline image
The XLH Network and Kyowa Kirin Launch the XLH Community Guidebook to Help People Navigate Lifelong Journey with XLH
From Kyowa Kirin
Via GlobeNewswire
News headline image
Kyowa Kirin to Present New Complementary Evidence Further Defining Clinical Utility of Mogamulizumab in Cutaneous T-Cell Lymphoma at 2026 WCCL
From Kyowa Kirin
Via GlobeNewswire
News headline image
FDA Approves New Dosing Option for CRYSVITA® (burosumab-twza) in Adults With XLH
From Kyowa Kirin
Via GlobeNewswire
News headline image
Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML
From Kyowa Kirin
Via GlobeNewswire
News headline image
Kyowa Kirin Announces Discontinuation of Rocatinlimab Clinical Trials
From Kyowa Kirin
Via GlobeNewswire
News headline image
Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis
From Kyowa Kirin
Via GlobeNewswire
News headline image
Kyowa Kirin Announces Proposed Appointment of Abdul Mullick to President and Chief Executive Officer, While Former CEO Masashi Miyamoto to Remain Chairman
From Kyowa Kirin
Via Business Wire
News headline image
Kyowa Kirin to Present New Research Highlighting Mogamulizumab’s Clinical Utility and Strategic Potential in T-Cell Lymphomas at 2025 ASH Annual Meeting
From Kyowa Kirin
Via GlobeNewswire
News headline image
Kyowa Kirin Announces Late-Breaking Abstract Presentation at the European Academy of Dermatology and Venerology Congress
From Kyowa Kirin
Via GlobeNewswire
News headline image
Amgen and Kyowa Kirin Announce Top-Line Results From Rocatinlimab Phase 3 ASCEND Long-Term Extension Study in Adults With Moderate to Severe Atopic Dermatitis
From Kyowa Kirin
Via GlobeNewswire
Tickers AMGN
News headline image
Kyowa Kirin Premiers New CTCL Staging Tool for Healthcare Providers
From Kyowa Kirin
Via GlobeNewswire